All In Biotech

Drug Trial Radar · NCT02204501

A Drug-Drug Interaction Study to Evaluate the Effect of Vapendavir on the Pharmacokinetics of Midazolam in Healthy Male and Female Volunteers

A Phase 1, Randomized, Open-Label Study to Evaluate the Effect of Vapendavir (BTA798) on the Pharmacokinetics of Orally Administered Midazolam, a CYP3A4 Substrate, in Healthy Male and Female Volunteers

Last checked: Nov 19, 2026Latest source record: May 30, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

24

Actual

Start

May 2014

Primary completion

Jun 2014

Study completion Jun 2014

Sponsor

Sponsor type
Industry
First posted
Jul 30, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Single group
Masking
None
Primary purpose
Other
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The primary aim of this Phase 1 study is to evaluate the effect of vapendavir daily doses of 528 mg daily (QD) and 264 mg twice daily (BID) on the pharmacokinetic (PK) profile of midazolam, a cytochrome (CYP) 3A4 substrate. Additionally, the effect of midazolam on the PK profile of vapendavir, a PK profile comparison of vapendavir in males and females, as well as the safety of vapendavir will also be assessed.

Conditions

  • Drug-Drug Interaction Healthy Volunteers

Interventions

  • Midazolam 5mg SyrupDrug

    All twenty four subjects will receive 5 mg midazolam syrup at four different time points during the study for a total of four non-subsequent dosing days. * On Study Days 0 and 12, subjects will receive only 5 mg midazolam syrup dosed in the morning. * On Study Days 6 and 9, subjects will have 5 mg midazolam syrup co-administered with their assigned dose of vapendavir in the morning. Co-administration of midazolam will not occur at the time of the evening dose for Group B.

  • Vapendavir 264 mg BIDDrug

    Twelve subjects (6 male and 6 female) will receive 264 mg vapendavir (achieved with two 132 mg vapendavir capsules) BID daily as divided dose given in the morning and evening 12 hours apart for seven days.

  • Vapendavir 528 mg QDDrug

    Twelve subjects (6 male and 6 female) will receive 528 mg vapendavir (achieved with four 132 mg vapendavir capsules) QD in the morning for seven days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The Effect of Vapendavir on the PK Profile of MidazolamTime frame: End of Study (up to 46 weeks in duration)
  2. The Effect of Vapendavir on the PK Profile of MidazolamTime frame: End of Study (up to 46 weeks in duration)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Prism Clinical Research

    Saint Paul, Minnesota

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.